Formulation and Evaluation of Anti-Diabetic Inlay Tablets. by Reepa Patel, K
FORMULATION AND EVALUATION OF ANTI-DIABETIC 
INLAY TABLETS 
  
Dissertation submitted to 
THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY, CHENNAI 
In partial fulfillment of the requirement for the award of the degree of 
MASTER OF PHARMACY 
(PHARMACEUTICS) 
Submitted By 
Reg. No: 26104207 
Under the guidance of 
Dr. S. TAMIZHARASI, M.Pharm., PhD., 
Head of the Department, 
Department of Pharmaceutics 
 
 
MAY - 2012 
NANDHA COLLEGE OF PHARMACY 
AND RESEARCH INSTITUTE, 
ERODE – 638 052, TAMILNADU 
 Dr. S. TAMIZHARASI, M.Pharm., Ph.D. 
Head of the department, 
Department of pharmaceutics, 
Nandha College of Pharmacy, Erode – 638 052. 
 
CERTIFICATE 
 
 
                   This is to certify that the work embodied in this thesis entitled “FORMULATION AND 
EVALUATION OF ANTI-DIABETIC INLAY TABLETS” submitted to The Tamilnadu Dr. M.G.R. 
Medical University, Chennai, was carried out by Ms. REEPA PATEL.K (Reg.No.26104207) in the 
Department of Pharmaceutics, Nandha College of Pharmacy, Erode-52 in partial fulfillment for the 
degree of MASTER OF PHARMACY in Pharmaceutics under my direct supervision and guidance.  
 
This work is original and has not been submitted in part or full for any other degree or 
diploma of any university. 
 
 
 
 
 
Place: Erode       Dr. S. TAMIZHARASI, M.Pharm., Ph.D. 
 
 
Date:                                                           Research Guide 
 
 
 
 
EVALUATION CERTIFICATE 
 
            This is to certify that the work embodied in this thesis entitled, “FORMULATION AND 
EVALUATION OF ANTI-DIABETIC INLAY TABLETS” submitted to The Tamil Nadu Dr. 
M.G.R. Medical University, Chennai, was carried out by Reg. No. 26104207  in the Department 
of Pharmaceutics, Nandha College of Pharmacy and Research institute, Erode-52 for the partial 
fulfillment for the award of degree of MASTER OF PHARMACY in Pharmaceutics under the 
supervision and guidance of Dr.S.THAMIZARASI, M.Pharm., PhD., Head of the department, 
Department of Pharmaceutics, Nandha College of Pharmacy and Research Institute, Erode- 52. 
 
This work is original and has not been submitted in part or full for any other degree or 
diploma of this or any other university. 
 
 
 
 
Internal Examiner                         External Examiner 
 
 
 
 
 
 
 
 
  
DECLARATION 
 
 
The work presented in this thesis entitled “FORMULATION AND EVALUATION OF 
ANTI-DIABETIC INLAY TABLETS” was carried out by me in the Department of 
Pharmaceutics, Nandha College of Pharmacy, Erode, under the direct supervision and guidance of 
Dr. S. TAMIZHARASI M.Pharm., Ph.D., Nandha College of  Pharmacy, Erode -52. 
This work is original and has not been submitted in part or full for any other degree or 
diploma of any university. 
 
 
 
 
Place: Erode           K.Reepa Patel 
Date:            Reg.No.26104207 
                                                                                                                   M. Pharm, II Year 
  Nandha college of Pharmacy 
                                                                                                                   Erode – 052 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ACKNOWLEDGEMENT 
                  It is moment of gratification and pride to look back with a sense of 
contentment at a long travelled path, to be able to capture some of the fine moments, to 
be able to thank infinite number of people, some who were with me from the beginning, 
some who joined me at some stage during the journey, whose kindness, love and blessing 
has brought this day. I wish to thank each one of them with all my heart. 
                  It is my great pleasure to thank my eminently esteemed teacher and guide Dr. 
(Mrs.) S. Tamizharasi, M.Pharm., Ph.D., Head, Dept. of Pharmaceutics, Nandha 
College of Pharmacy, Erode, for her valuable guidance, keen interest, inspiration, 
encouragement and moral support throughout my dissertation work. 
         I take the opportunity to express my heartfelt gratitude to our principal 
Dr.T.Sivakumar, M.Pharm., Ph.D., Principal, Nandha College of Pharmacy, Erode, 
with a deep sense of gratitude for encouragement, co-operation, kind suggestions and 
providing the best facilities during this work. 
         I thank honorable Thiru V. Shanmugan, B.Com., Chairman and 
Mr.S.Nandhakumar Pradeep, M.B.A., Secretary, Nandha College of Pharmacy, Erode-
52, for providing me the required infrastructure to undergo my study. 
        I owe my warmest and humble thanks to Dr. Sengotuvelu, M.Pharm., Ph.D., Head, 
Dept. of Pharmacology and Prof. R. Rajvel, M.Pharm., Dept. of Pharmaceutical 
chemistry, for their immense help throughout the courses of study. 
        I also feel pleasure in expressing sincere thanks to respected teachers Prof. Dr. 
P.R.Radhika, M.Pharm., Ph.D., Prof. Amsa, M.Pharm., and Prof. K.Raja, M.Pharm.,  
who constantly supported me in my every needful moment. 
        I want to say extremely special thanks to my friend A.L.Jayashankar for providing 
the necessary help. 
        I also express my thanks to our non-teaching staff for providing timely assistance 
throughout the entire work. 
        I convey our thanks and gratitude to our college Librarian for providing references 
in time. 
        It gives me profound pleasure to express my heartful thanks to my classmates 
Pavani, Sanath, Sibu, Kalpana, Rajnish, Ravi, Praveen, Prakash, Subhash, and 
Thandav Krishna for their constant inspiration and co-operation. 
        Last but not least, I express my heartiest thanks and gratitude to Rushi, my beloved 
Parents and all my Relatives for all their blessings without which my project would be 
incomplete. 
        Besides this, several people have knowingly and unknowingly helped me in the 
successful completion of this project. I thank every one of them. 
 
 
    Place: Erode                                                                       Reg. No: 26104207 
    Date:                                                                                   M.Pharm, II Year, 
                                                                        Pharmaceutics, 
                                                                                               Nandha College of Pharmacy, 
                                                          Erode. 
CONTENTS 
S.No Titles  Page No. 
1 INTRODUCTION 1-6 
1.1 tablets 1 
1.2 Inlay tablets  3 
1.3  Immediate release tablets  4 
1.4 Sustained release tablets 5 
1.5 Diabetes mellitus 5 
2 LITERATURE REVIEW 7-12 
3 AIM  13 
4 PLAN OF WORK 14 
5 DRUG PROFILE 15-19 
6 EXCIPIENT PROFILE 20-28 
7 MATERIALS AND METHODS 29-42 
7.1 Preformulation studies 30 
7.2 Formulation development 31 
7.3 Pre compression studies on granules 33 
7.4 Post compression studies of tablets 36 
8 RESULTS AND DISCUSSION 43-71 
8.1 Preformulation studies 43 
8.2 Precompression study sr formulation 54 
8.3 Post compression studies of sr tablets 55 
8.4 Pre compression study for ir formulation 59 
8.5 Post compression of ir tablet 60 
8.6 Formulation and evaluation of inlay tablets 63 
9 SUMMARY AND CONCLUSION 72 
10 REFERENCES 74 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LIST OF TABLES 
S.No Table Page No 
1. List of materials and their applications in formulation 30 
2. Equipments used for the Research Work 31 
3. Formulation of SR tablets 34 
4. Polymer concentration used with respect to drug Metformin HCl 34 
5. Formulation of IR tablets 35 
6. Angle of Repose as an Indication of Powder Flow Properties 37 
7. Relationship between % compressibility and flow ability 37 
8. Weight Variation Specification as per IP 38 
9. Limits for SR formulation release 41 
10. Description of diffusion mechanism 44 
11 Drug – Excipients Physical compatibility studies 46 
12. Calibration curve of Active ingredients 54 
13. Pre compression study SR formulation 56 
14. Post compression parameters of SR formulations 57 
15. In vitro dissolution profile SR tablet 58 
16. Pre compression study for IR formulation 61 
17. Post compression study of IR Tablet 63 
18. In vitro dissolution profile of IR tablet 63 
19. Formulation for inlay tablets 64 
20. Evaluation of inlay tablets 65 
21. Swelling and erosion behaviour of inlay tablets 65 
22. Drug content of the inlay tablet 66 
23. In vitro dissolution profile of SR and IR layer 66 
24. Data for various kinetic models 67 
25. Data for various kinetic models 70 
26. Stability study at 40˚C/75% RH 72 
27. Assay and dissolution profile of inlay tablet at stability study at 
40˚C/75% RH   
73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
LIST OF FIGURES 
S.No Figures Page No 
1. Inlay Tablets 4 
2. Structure of Metformin HCl 16 
3. Structure of Gliclazide 18 
4. Spectrum of Metformin HCl 44 
5. Spectrum of Gliclazide 45 
6. IR spectra of Metformin HCl 47 
7. IR spectra of Gliclazide 47 
8. IR spectra of Metformin HCl + Gliclazide 48 
9. IR spectra of HPMC 48 
10. IR spectra of Xanthan gum 49 
11. IR spectra of Sodium starch glycolate 49 
12. IR spectra of Croscarmellose sodium 50 
13. IR spectra of Crospovidone 50 
14. IR spectra of Metformin HCl + HPMC 51 
15. IR spectra of Metformin HCl + Xanthan gum 51 
16. IR spectra of Gliclazide + Sodium starch glycolate 52 
17.  IR spectra of Gliclazide + Croscarmellose sodium 52 
18. IR spectra of Gliclazide + Crospovidone 53 
19. Calibration curve of Metformin HCl 54 
20. Calibration curve of Gliclazide 55 
21. Comparitive dissolution profile of F1, F2,F3 
 
59 
22. Comparitive dissolution profile of F4, F5, F6 59 
23. In Vitro dissolution profile of various SR formulations 60 
24. In Vitro dissolution profile of various IR formulations 64 
25. Zero order kinetics of SR 67 
26. First order kinetics of SR 68 
27. Higuchi diffusion kinetics of SR 68 
28. Hixson Crowell equation of SR 69 
29. Korsmeyer Peppas equation of SR 69 
30. First order kinetics of IR 71 
31. Zero order kinetics of IR 71 
 
 
 
 
 
 
 
 
 
 LIST OF ABBREVIATIONS 
%                    -          percentage 
Kg                  –          kilogram 
Gm                 –          gram 
Mg                 –          milligram 
µg                  –          microgram 
ml                  –          millilitre 
°C                  –          centigrade 
Nm                –          nanometer 
µl                  –           microliter 
CI                 –           carr’s index 
Mm               –          millimetre 
HPLC           –           high performance liquid chromatography 
UV               –            ultra-violet spectrophotometer 
HPMC          –           hydroxypropyl methyl cellulose 
MCCP          –           micro crystalline cellulose powder 
SSG              -            sodium starch glycholate 
Mins             –           minutes 
RH                –           relative humidity 
USP              –           united states pharmacopoeia 
NF                –           national formulary 
BP                –           british pharmacopoeia 
ICH              –           international conference on harmonisation 
#                   -             mesh 
SD                –            standard deviation 
Abs               –            absorbance 
IR                  –           immediate release 
SR                 –           sustained release 
Cm                –           centimetre 
Con               –           concentration  
F                    -            formulation   
 
                                                                                           Introduction 
 
Nandha College of Pharmacy, Erode Page 1 
 
1. INTRODUCTION 
1.1.TABLETS 
1
: 
            Tablets are defined as solid pharmaceutical dosage forms containing drug substances 
with or without suitable diluents and prepared by either compression or molding methods. 
Tablets remain popular because of the advantages afforded both to the manufacturer (eg: 
simplicity and economy of preparation, stability and convenience in packaging, shipping and 
dispensing) and the patient (eg: accuracy of dosage, compactness, portability). They vary in 
shape, size and weight depending upon the amount of drug substance present and the 
intended method of administration. It is the most popular dosage form and 70% of the total 
medicines are dispensed in the form of tablets. 
Advantages of tablets: 
1. They are a unit dose form, and they offer the greatest capabilities of all oral dosage 
forms for the greatest dose precision and the least content variability. 
2. Their cost is lowest of all oral dosage forms. 
3. They are the lightest and most compact of all oral dosage forms. 
4. They are in general the easiest and cheapest to package and ship of all oral dosage 
forms. 
5. Product identification is potentially the simplest and cheapest, requiring no additional 
processing steps when employing an embossed or monogrammed punch face. 
6. They may provide greatest ease of swallowing with the least tendency for hang-up 
above the stomach, especially when coated, provided that tablet disintegration is not 
excessively rapid. 
7. They lend themselves to certain special release profile products, such as enteric or 
delayed-release products. 
8. They are better suited to large-scale production than other unit oral dosage forms. 
9. They have the best combined properties of chemical, mechanical, microbiologic 
stability of all the oral forms. 
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Disadvantages of tablets: 
1. They are difficult to swallow in case of paediatric, geriatric, unconscious patients. 
2. Some drugs resist compression into dense compacts, owing to their amorphous nature 
or flocculent, low density character. 
3. Drugs with poor wetting, sloe dissolution properties, optimum absorption or any 
combination of these features may be difficult or impossible to formulate and 
manufacture as a tablet that will still provide adequate or full drug bioavailability. 
4. Bitter tasting drugs, drugs with an objectionable odour or drugs that are sensitive to 
oxygen or atmospheric moisture may require encapsulation or coating. 
Types of Tablets: 
           Tablets are mainly classified into 4 categories according to their route of 
administration. The following are the 4 groups. 
I. Oral tablets for ingestion 
a. Standard compressed tablets 
b. Multiple compressed tablets 
• Compression coated tablet 
• Layered tablet 
• Inlay tablet 
c. Modified Release tablet 
d. Delayed action tablet 
e. Targeted tablet 
• Floating tablet 
• Colon targeting tablet 
f. Chewable tablet 
g. Dispersible tablet 
  
II. Tablets used in the oral cavity 
a. Lozenges and troches 
b. Sublingual tablet 
c. Buccal tablet 
d. Dental cones 
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e. Mouth dissolved tablet 
III. Tablets administered by other routes 
a. Vaginal tablet 
b. Implants 
IV. Tablets used to prepare solution 
a. Effervescent tablet 
b. Hypodermic tablet 
c. Soluble tablet 
                      With advancement in technology and increase in awareness towards 
modification in standard tablet to achieve better acceptability as well as bioavailability, newer 
and more efficient tablet dosage form are developed. 
I. Bilayer tablet 
II. Multilayer tablet 
III. Inlayer tablet 
IV. Inlay tablet 
1.2.INLAY TABLETS 
2
: 
              A variation of the compression coated tablet is the inlay tablet. In the inlay tablet, 
instead of the core tablet being completely surrounded by the coating, its top surface is 
completely exposed i.e., only the bottom layer of the coating is deposited in the die and core 
is placed on it. It is a dosage form comprising of high dose, high solubility active ingredient 
as modified release and a low dose active ingredient as immediate release where the weight 
ratio of immediate release active ingredient and modified release active ingredient is from 
1:10 to 1:15000 and the weight of modified release high dose high solubility active ingredient 
per unit is from 500 mg to 1500 mg and the weight of immediate release active ingredient is 
up to 50 mg. 
              The dosage form consists of two parts, core portion as an immediate release and cup 
portion as modified release.  
 The core portion consists of super disintegrant, low dose drug and excipients. 
  The cup portion consists of high dose, high solubility active ingredient, hydrophilic 
release controlling agent and excipients 
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                                Fig No.1 Inlay Tablets 
     
Advantages of inlay tablets over compression coated and layered tablets: 
1. It requires less coating material. 
2. Core is visible so core less tablets are easily detected. 
3. The reduction in the amount of coating makes for a thinner tablet. 
4. It effectively avoids the problem of separation of layers of multi-layered tablets. 
5. It gives accurate dosing and is prepared by conventional and simple process. 
6. It further teaches the use of hydrophilic release controlling agents which do not hinder 
the release of immediate release active ingredient. 
7. Freedom from capping of top coating. 
1.3.Immediate release tablets 
3
: 
             Immediate release solid oral dosage forms are classified as either having rapid or 
slow dissolution rates. Immediate release dosage forms are those for which ≥85% of labelled 
amount dissolves within 30 min. For immediate release tablets, the only barrier to drug 
release is simple disintegration or erosion stage, which is generally accomplished in less than 
one hour1. To enhance dissolution and hence bioavailability of any drug from immediate 
release tablets, disintegration is one of the important process. Few Super-disintegrants are 
available commercially as Croscarmellose sodium, Crospovidone and SSG. 
              Super disintegrants play a major role in the disintegration and dissolution of MDT. 
Super disintegrants provide quick disintegration due to combined effect of swelling and water 
absorption by the formulation which forms a porous structure. The optimum concentration of 
the superdisintegrant can be selected according to critical concentration of disintegrant. 
Below this concentration, the tablet disintegration time is inversely proportional to the 
concentration of the superdisintegrant, whereas if concentration of superdisintegrant is above 
critical concentration, the disintegration time remains almost constant or even increases. 
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1.4.Sustained release dosage form 
4
: 
          Conventional drug delivery systems are used in treatment of an acute disease or a 
chronic disease using various pharmaceutical dosage forms including tablets, capsules, pills, 
suppositories, creams, ointments, liquids, aerosols and injectables as drug carriers. This type 
of drug delivery system is known to provide a prompt release of drug. Therefore, to achieve 
as well as to maintain the drug concentration within therapeutically effective range needed 
for treatment, it is often necessary to take this type of delivery system several times a day. 
This results in significant fluctuations in drug levels. 
         To avoid the above disadvantage several techniques have been developed which are 
capable of controlling the rate of drug delivery, sustaining duration of therapeutic activity, 
and/or targeting the delivery of drug to tissue. 
       Sustained release can be described as a pharmaceutical dosage form formulated to retard 
the release of therapeutic agent such that its appearance in systemic circulation is delayed 
and/or prolonged and its plasma profile is sustained in duration. 
 Advantages of sustained release drug delivery system: 
1. Reduction in dosing frequency. 
2. Reduced fluctuations in circulating drug levels. 
3. Avoidance of night time dosing. 
4. Increased patient compliance. 
5. More uniform effect. 
6. Decreased side effects like reduced GI irritation. 
              
1.5.DIABETES MELLITUS:  
              Diabetes mellitus, often simply referred to as diabetes, is a group of metabolic 
diseases in which a person has high blood sugar, either because the body does not produce 
enough insulin, or because cells do not respond to the insulin that is produced. 
Signs and symptoms: 
            The classical symptoms of diabetes are  
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 polyuria (frequent urination) 
 polydipsia (increased thirst)  
 polyphagia (increased hunger) 
 blurred vision 
 diabetic dermadromes (skin rashes) 
Causes: 
              Insulin is a hormone produced by the pancreas to control blood sugar. Diabetes can 
be caused by too little insulin, resistance to insulin, or both. This is because: 
 The pancreas does not produce enough insulin. 
 The muscle, fat, and liver cells do not respond to insulin normally. 
 Both of the above. 
Diagnosis: 
               Diabetes mellitus is characterized by recurrent or persistent hyperglycemia, and is 
diagnosed by demonstrating any one of the following: 
The cut off samples of venous plasma samples are: 
Fasting blood sugar = 126 mg/dl (after minimum 8 hrs of fasting) 
Random blood sugar = 200 mg/dl (sample taken at any time of the day) 
Post prandial blood sugar = 200 mg/dl (2 hrs postprandial state) 
Oral glucose tolerance test is the gold standard for diagnosis. 
Categorizing diabetes mellitus: 
There are three major types of diabetes: 
Type 1 diabetes is usually diagnosed in childhood. Many patients are diagnosed when they 
are older than age 20. The body makes little or no insulin. Daily injections of insulin are 
needed. The exact cause is unknown. Genetics, viruses and autoimmune problems play a 
major role. 
Type 2 diabetes is far more common than type 1. It makes up most of diabetes cases. It 
usually occurs in adulthood, but young people are increasingly being diagnosed with this 
disease. The pancreas does not make enough insulin to keep blood glucose levels normal, 
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often because the body does not respond well to insulin. Many people with type 2 diabetes do 
not know they have it, although it is a serious condition. Type 2 diabetes is becoming more 
common due to increasing obesity and failure to exercise. 
Gestational diabetes is high blood glucose that develops at any time during pregnancy in a 
woman who does not have diabetes. 
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2. LITERATURE REVIEW 
Kotta Kranthi Kumar et al 
5
., Reported that Bilayer tablets of Metformin Hydrochloride 
and gliclazide was successfully formulated and evaluated. The investigation was aimed to 
the development of bilayered tablets of metformin hydrochloride and gliclazide as 
sustained release by using HPMC as retardant. The best formula was selected by physical 
evaluation of tablets, comparative dissolution profiles and similarity factor correlation 
studies of various formulations of metformin hydrochloride and gliclazide.  
N. N. Rajendran et al 
6
., Concluded that Bilayer tablets of Pioglitazone HCl and 
Metformin HCl as an alternative to the conventional dosage form. Sustained layer of 
metformin were prepared by wet granulation method using different viscosity grade of 
HPMC as polymers and immediate release layer were prepared by direct compression 
using superdisindegrants such as SSG and crosscarmellose sodium. The result showed 
that combinations of polymers HPMC K100M and HPMCK4M in sustained layer can 
control the release of drug. 
AR Mullaicharam et al 
7
., Developed once daily sustained release matrix tablets of 
metoprolol tartrate with inlay hydrochlorthiazide tablet as immediate release. Both the 
layers were prepared by wet granulation method. Five trial batches of sustained release 
granules were prepared using HPMC in various percentages and one optimum 
formulation was selected among them on basis of in vitro dissolution studies. 
Yamsani Madhusudan Rao et al 
8
.,  Reported that formulated bilayer tablets provided 
immediate release of glimepiride and metformin HCl as sustained release over a period of 
8 hours.The immediate release layer was prepared using sodium starch glycolate as super 
disintegrant and sustained release using HPMC K4M and sodium carboxy methyl 
cellulose as polymers and PVP K30 as binder. Formulation containing higher 
concentration of sodium starch glycolate and SCMC in IR and SR layer respectively were 
optimised for bilayer tablets. 
Manoranjan Sahu et al 
9
., Concluded that modified inlayered tablet containing 
glimepiride as immediate release and metformin as sustained release was designed to 
improve oral therapeutic efficacy. Tablet compressing was done with core rod tooling 
where only one surface of core is exposed to outside and other drug is incorporated in cup 
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portion. Common analytical method was developed for quantitative combined drug 
estimation. 
Laxmi Goswami et al 
10
., Concluded that formulated floating bilayer tablets of 
metformin and pioglitazone remain buoyant over a period of 12-20 hours and released 
more than 80% of drug. The tablets were formulated by modified direct compression 
using polymers like HPMC, carbopol, PVP to facilitate immediate release of pioglitazone 
and sustained release of metformin and were subjected to various evaluation parameters 
including floating lag time, floating duration, drug content and spectrophotometric 
simultaneous estimation. 
J. Bagyalakshmi et al
 11
., Reported that bilayer matrix tablet containing 500mg of 
metformin HCl as SR from one layer and 5mg glipizide as IR from another layer can be 
prepared by solid dispersion method. Solubilty of glipizide was increased by solid 
dispersion technique with sodium starch glycolate using kneading technique. Metformin 
was formulated using different grades of HPMC. 
Chitra. P et al 
12
.,   Formulated and optimized once daily sustained release inlay tablet of 
propranolol hydrochloride and hydrochlorthiazide.SR active ingredient is selected from 
higher dose and IR active ingredient is selected from lower dose. Tablets were evaluated 
for hardness, thickness, uniformity of weight, friability, content uniformity, in-vitro drug 
release. Optimized formulation could extend release of PRO for 24 hrs and HCTZ for 15 
mins. 
Tapan Kumar Pal et al 
13
., Concluded that the study helped in finding optimum 
formulation of Metformin HCl with sustained drug release. Tablets were prepared by 
non-aqueous wet granulation method using HPMC K15M as matrix forming polymer. 
Drug release profile was formulated using response surface methodology. Indepependant 
variables were HPMC K15M and PVP K30 whereas dependant variables were % of drug 
released in 1hr, 8 hrs and time to 50% drug release. 
Sahu Manoranjan 
14
., Reported that the designed inlayered tablet of glimepiride as 
immediate release and metformin hydrochloride  as sustained release indicated suitability 
for patient compliance. Inner core portion was desingned using superdisintegrants for 
immediate release and outer cup portion was designed using polymers such as HPMC and 
PVP to modulate drug release. 
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P. Jeyaprabha et al 
15
., Prepared a modified release tablet of gliclazide by using different 
grades of hydroxypropyl cellulose. Release process involved erosion and diffusion 
mechanism. Among all the 9 formulations prepared, formulation F9 with GXF 15% cum 
EXF 12% had good release and highest f2 (56.9) value, therefore it was decided to 
comparable with innovator F1. 
Poonam S. Karekar et al 
16
., Proposed spectrophotometric method for the estimation 
gliclazide in bulk and pharmaceutical dosage form. Wavelength maxima for gliclazide 
was found to be 229.5nm with molar absorptivity of 1.4962×10
4l/mol/cm. Beer’s law was 
obeyed in the concentration range of 7-27 µg/ml. The limit of detection (LOD) and limit 
of quantification (LOQ) were found to be 0.31µg/ml and 0.92 µg/ml. Percentage recovery 
of drug for the proposed method ranged from 98.68-100.12% indicating no interference 
of the tablet excipients. 
Tanbir Ahammad et al 
17
., Prepared matrix tablets of gliclazide by direct compression 
and wet granulation process using Methocel K15M CR, studied effect of  granulation 
process on drug release and found that wet granulation extend release more than that of 
direct compression technique. 
Shinde Anilkumar J et al 
18
., Prepared fast dissolving tablets of gliclazide by direct 
compression method using superdisintegrants crosspovidone and croscarmellose sodium 
with binders PVP K30 and pregelatinised starch and concluded that Croscarmellose 
sodium was best superdisintegrant with PVP K30 as binding agent showing more than 
99% of drug release within 12 minutes. 
Chauhan Pratik Navinchandra et al 
19
., Developed mouth dissolving tablets of 
gliclazide using three super disintegrants hypromellose, crosspovidone and sodium starch 
glycolate at different concentrations with microcrystalline by direct compression. Among 
all the twelve formulations crosspovidone F6 emerged as overall best formulation due to 
its fast invitro dispersion when compared to other formulations and 97% drug release 
within 15 min. 
Raja Rajeswari K et al 
20
., Developed modified release hydrogel formulations of a 
poorly soluble drug, Gliclazide using a hydrophilic polymer HPMC in two grades i.e., 
HPMC 15cps and Methocel K4M. All six formulations were developed and evaluated for 
invitro drug release upto 16hrs and compared with that of marketed formulation. GMF VI 
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was found to have similar release pattern proving to show controlled release following 
zero order release by anomalous diffusion. 
S. Chandra et al 
21
., Prepared fast dissolving tablets of gliclazide using solid dispersion 
and various concentrations of superdisintegrant agents like Ac-Di-Sol, Crospovidone, 
sodium starch glycolate by direct compression method. Among nine formulations, tablets 
of batch F6 containing Crospovidone and Avicel 102 showed super organoleptic 
properties along excellent invitro disintegration time and drug release as compare to other 
formulations. 
Mahendra labana et al 
22
., Designed modified release gliclazide by direct compression 
using HPMC as polymer, Dibasic calcium phosphate and maltodextrin as binder. The 
prepared formulations were further evaluated for hardness, friability, drug content 
uniformity, in vitro dissolution time and short term stability and drug excipient interaction 
were studied. 
Narendra Sharma et al 
23
., Developed second derivative spectrophotometric method for 
determination of metformin hydrochloride in bulk and in tablet dosage form. The 
quantitative determination of the drug was carried out using the second derivative values 
measured at 233.8 nm. Calibration graph constructed at 233.8 nm was linear in 
concentration range of 4-20 μg/ml with correlation coefficient 0.9979. The method was 
validated as per ICH guidelines and can be used for determination of Metformin 
hydrochloride in tablet dosage form. 
S A Patil et al 
24
., Formulated solid dispersion of metformin hydrochloride using 
methocel K100M as carrier by solvent evaporation and cogrinding method. Solid 
dispersion with 1:4 and 1:5 ratio of drug to polymer obtained by solvent evaporation and 
cogrinding were selected as best candidates suitable for prolonged release oral dosage 
form of metformin. 
Dr K.L.Senthilkumar et al 
25
., Formulated and evaluated metformin sustain release 
tablets using different polymers as release retarding agent and concluded that formulation 
of sustained release tablet of metformin containing 13% HPMC K100 with binder PVP 
K30 was found to be ideal or optimized formulation of sustained release tablets for 10 
hour release as it fulfils all the requirements for sustained release tablet. 
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M. M. Varma et al 
26
., Designed gastroretentive floating drug delivery system of 
metformin hydrochloride using HPMC K4M and carbopol 934P as polymers and sodium 
bicarbonate as gas generating agent by wet granulation method. Release of metformin 
HCl from the floating tablets formulated with HPMC and /carbopol was slow and spread 
over 12 h and depended on % of polymer in the tablet. Batch F4 (carbopol 934P 150 mg, 
sodium bicarbonate 50 mg) showed better sustained release than other formulations. 
N. Aruna et al 
27
., Formulated metformin HCl sustained release matrix tablet using 
Syzygium cumini as a release retarding agent which is antidiabetic in nature using various 
polymers HPMC K100M, Eudragit RLPO, Carbopol940, Ethyl cellulose by wet 
granulation method. Formulation containing HPMC K100M and ethyl cellulose showed 
sustained drug release pattern upto 12 hrs which matched drug release pattern of 
innovator. 
Sunil Kumar et al 
28
., Designed extended release metformin tablet by wet granulation 
method using HPMC K100M as polymer, stearic acid and IPA as binder. The prepared 
formulations were further evaluated for hardness, friability, drug content uniformity, in 
vitro dissolution time and for in vitro drug release pattern in pH 6.8 phosphate buffer and 
short term stability and drug-excipient interaction were studied. 
Manju Nagpal et al 
29
., Developed oro-dispersible tablets of metformin by direct 
compression method using super disintegrants, effervescent and sublimation approach. 
Batch C4 prepared by effervescent approach was found to have the least disintegration 
time and maximum in vitro dissolution profile. 
Margret Chandira et al 
30
., Formulated extended release matrix tablet of metformin 
hydrochloride using different combinations of polymers HPMC K100M CR and carbopol 
71 G by wet granulation method. Formulations F7, F9 and F10 containing HPMC K 100 
M CR and Carbopol 71G in different concentration shows the extended drug release for 
up to 10 hrs, among these formulation, F10 is considered as optimized formulation 
because it shows similar drug release pattern with that of innovator. 
Harrower AD et al 
31
., Performed studies to assess the efficacy of various sulfonyl ureas 
in the management of diet failed NIDDM patients. The results showed that gliclazide is a 
potent hypoglycaemic agent having low incidence of side effects, few problems with 
hypoglycaemia and retains its efficacy longer than other sulfonylureas. 
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Pareek et al 
32
., Evaluated efficacy and tolerability of gliclazide and metformin 
combination and found that addition of gliclazide to metformin is an effective treatment 
for inadequately controlled patients on sulfonyl urea or metformin alone and its 
combination achieves good glycemic control and improves lipid levels with better 
tolerability. 
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3. AIM AND OBJECTIVE 
To provide effective, safe and stable pharmaceutical oral formulation of inlay tablet 
containing both immediate release and sustained release of two antidiabetic drugs with 
different mechanisms of action to improve glycemic control. 
                                 Diabetes a global public health problem is a chronic disease and is now 
growing as an epidemic in both developed and developing countries. It occurs in two forms 
Type I and Type II. Type II is more common which can be treated by giving insulin or oral 
hypoglycemic agents. Upon progression of the disease, progressive loss of β-cell function 
and mass makes it difficult for patients to maintain glycemic control with monotherapy. As a 
result, combination therapy involving agents with complementary mechanism of action is the 
next logical step in the management of T2DM. 
                                     Metformin hydrochloride (MH), is the first choice of drug among all 
the oral hypoglycemic patients as it lowers both basal- and postprandial-elevated blood 
glucose in patients with non-insulin-dependent diabetes mellitus, does not lead to weight gain 
and has been shown to possess lipid-lowering properties.  Since metformin lowers plasma 
glucose without affecting insulin secretion, it is often combined with an agent stimulating 
insulin secretion, like a sulfonylurea. Adding a sulfonylurea to metformin has thus been the 
conventional and the gold standard combination therapy for decades. Gliclazide is the first 
choice among all the sulfonyl urea because of its low incidence of side effects and secondary 
failure, few problems with hypoglycaemia. 
                           Metformin HCl is formulated as sustained release because gastrointestinal 
absorption of metformin is incomplete with an absolute bioavailability of 40–60% (under 
fasting conditions) in combination with rapid elimination and 20–30% of an oral dose is 
recovered in faeces. Side effects and the need for twice to three times a day administration 
when larger doses are required can also reduce patient compliance. Therefore due to all the 
above drawbacks it is necessary to formulate Metformin HCl as SR to reduce dosing 
frequency and improve patient compliance. 
                           Gliclazide is formulated as immediate release using super disintegrant as it 
has very long half life of 6-8 hrs to increase insulin secretion as soon as it is administered.          
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4. PLAN OF WORK 
 Raw material analysis 
 Preformulation studies 
                  Melting point determination of active ingredients 
                  Determination of λ max 
                  Drug-Excipient Physical compatability studies 
                  Chemical compatability studies – by FTIR 
                  Calibration curve 
 Formulation of sustained release tablets 
      By using different polymers with different concentrations 
      Pre compression study of tablet 
      Post compression study of tablets 
 Formulation of immediate release tablets 
    By using different concentrations of disintegrants 
    Pre compression study of tablet 
    Post compression study of tablet 
 Optimization of formulation with respect to in vitro release profile of SR and IR 
tablets 
 Formulation of Inlay tablets 
 Evaluation of Inlay tablets 
 Evaluation of Swelling and Erosion behaviour of the Inlay tablets 
 Determination of in vitro release kinetic studies for the Inlay tablets. 
 Determination of stability of Inlay tablets as per ICH Guidelines. 
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5. DRUG PROFILE 
METFORMIN HYDROCHLORIDE: 
            Metformin is an oral antidiabetic drug in the biguanide class. It is the first-line drug of 
choice for the treatment of type 2 diabetes, in particular, in overweight and obese people and 
those with normal kidney function. 
Chemical structure: 
                               Fig No. 2. Structure of Metformin HCl 
                                 
IUPAC name:  N,N-dimethylimidodicarbonimidic diamide 
Chemical formula: C4H11N5.HCl 
Molecular weight: 165.63 g/mol 
Category : hypoglycemic 
Dose : 0.5 to 3 g daily, in divided doses 
PROPERTIES: 
Description : white, crystalline powder hygroscopic 
Solubility : freely soluble in water; slightly soluble in ethanol (95%); practically insoluble in                    
acetone, chloroform, dichloromethane and ether. 
Melting point : 222-226˚C 
Storage : store in well closed container. 
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Mechanism of action: 
            Metformin improves hyperglycemia primarily by suppressing glucose production by 
the liver.  Metformin activates AMP-activated protein kinase (AMPK), an enzyme that plays 
an important role in insulin signaling, whole body energy balance, and the metabolism of 
glucose and fats. The mechanism by which biguanides increase the activity of AMPK 
remains uncertain; however, metformin increases the amount of cytosolic AMP.  In addition 
to suppressing hepatic glucose production, metformin increases insulin sensitivity, enhances 
peripheral glucose uptake (by phosphorylating GLUT-4 enhancer factor), increases fatty acid 
oxidation and decreases absorption of glucose from the gastrointestinal tract. Increased 
peripheral utilization of glucose may be due to improved insulin binding to insulin receptors. 
Bioavailability : 50 to 60% under fasting conditions 
Half life : 6.2 hours 
Plasma protein binding : negligible 
Volume of distribution : 300 – 1000 L 
Metabolism : none. 
Excretion : active renal tubular excretion. 
CONTRAINDICATIONS 
Hypersensitivity to drug. 
Acute or chronic metabolic acidosis with or without coma. 
Underlying renal dysfunction. 
Heart failure requiring drug therapy. 
ADMINISTRATION 
 Administer with a meal. 
 Make sure patient swallows extended release tablets whole without crushing or 
chewing. 
 Don’t administer extended release tablets to children. 
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DOSING INFORMATION 
 Usual Adult Metformin Dose for Diabetes Mellitus Type II:  
                    500 mg orally twice a day (with the morning and evening meal) 
 Extended Release: 
                  500 to 2000 mg orally once a day (with the evening meal). Maximum daily dose is 
2500 mg. 
ADVERSE REACTIONS 
            Diarrhea,  nausea, vomiting, abdominal bloating, abdominal cramping or pain, 
flatulence, anorexia. 
GLICLAZIDE: 
          Gliclazide is an oral hypoglycemic and is classified as a sulfonylurea.  
Structure: 
                           Fig No. 3  Structure of Gliclazide 
                      
 
IUPAC name : N-(hexahydrocyclopenta[c]pyrrol-2(1H)-ylcarbamoyl)-4 
methylbenzenesulfonamide. 
Molecular weight :  323.412 g/mol 
Molecular formula : C15H21N3O3S 
Pharmacologic class : sulfonyl urea 
Therapeutic class : hypoglycemic 
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Dose : 40- 320 mg daily, doses >160 mg daily may be given in 2 divided doses. 
Modified release tablets 30-120 mg daily. 
PROPERTIES: 
Description :   White, hydrophobic powder 
Solubility : Slightly soluble in water and soluble in methanol 
Melting point : 181
0
C 
Storage : store in well closed container. 
Mechanism of action:  
            Gliclazide selectively binds to sulfonylurea receptors (SUR-1) on the surface of the 
pancreatic beta-cells. It was shown to provide cardiovascular protection as it does not bind to 
sulfonylurea receptors (SUR-2A) in the heart. This binding effectively closes the K+ ion 
channels. This decreases the efflux of potassium from the cell which leads to the 
depolarization of the cell. This causes voltage dependent Ca++ ion channels to open 
increasing the Ca++ influx. The calcium can then bind to and activate calmodulin which in 
turn leads to exocystosis of insulin vesicles leading to insulin release. 
Half life : 10.4 hours 
Plasma protein binding   : 94%, highly bound to plasma proteins 
Metabolism  : Extensively metabolized in the liver 
Excretion  : Metabolites and conjugates are eliminated primarily by the kidneys (60-70%) 
and also in the feces (10-20%). 
Indications : 
            Gliclazide is used for control of hyperglycemia in gliclazide-responsive diabetes 
mellitus of stable, mild, non-ketosis prone, type 2 diabetes. It is used when diabetes cannot be 
controlled by proper dietary management and exercise or when insulin therapy is not 
appropriate. 
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Contraindications 
 Type 1 diabetes 
 Hypersensitivity to sulfonylureas 
 Severe renal or hepatic failure 
 Pregnancy and lactation 
 Miconazole coprescription 
Adverse effects: 
 Hypoglycemia - while it was proven to have the same efficacy as glimepiride, one of 
the newer sulfonylureas, the European GUIDE study has shown that it has 
approximately 50% fewer confirmed hypoglycaemic episodes in comparison with 
glimepiride. 
 Gastrointestinal disturbance (reported) 
 Skin reactions (rare) 
 Hematological disorders (rare) 
 Hepatic enzyme rises (exceptional)                                        
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SODIUM STARCH GLYCOLATE
 40
 : 
1. Nonproprietary Names : 
        BP         : Sodium Starch Glycollate 
        Ph Eur   : Carboxymethylamylum natricum 
        USPNF : Sodium starch glycolate 
2. Synonyms :  
        Carboxymethyl starch, sodium salt; Explosol; Explotab; Glycolys; Primojel; 
starch carboxymethyl ether, sodium salt; Tablo; Vivastar P. 
3. Chemical Name : 
         Sodium carboxymethyl starch. 
4. Structural Formula : 
              
5. Molecular weight : 
            5×10
5 _ 
1×10
6  
6. Functional Category : 
       Tablet and capsule disintegrant 
7. Applications in pharmaceutical formulation or technology : 
        Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant 
in capsule and tablet formulations. It is commonly used in tablets prepared by either 
direct compression or wet-granulation processes. The usual concentration employed 
in a formulation is between 2% and 8%, with the optimum concentration about 4%, 
although in many cases 2% is sufficient. Disintegration occurs by rapid uptake of 
water followed by rapid and enormous swelling. 
        Sodium starch glycolate has also been investigated for use as a suspending 
vehicle. 
8. Description : 
        Sodium starch glycolate is a white to off-white, odourless, tasteless, free-flowing 
powder.  
9. Typical Proprties : 
        Acidity / alkalinity : pH 3.0–5.0 or pH 5.5–7.5 for a 3.3% w/v aqueous 
dispersion. 
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CROSCARMELLOSE SODIUM 
40
: 
1. Nonproprietary Names : 
        BP         : Croscarmellose sodium 
        PhEur    : Carmellosum natrium conexum 
        USPNF : Croscarmellose sodium 
2. Synonyms :  
        Ac-Di-Sol; crosslinked carboxymethylcellulose sodium; Explocel; modified 
cellulose gum; Nymcel ZSX; Pharmacel XL; Primellose; Solutab; Vivasol. 
3. Chemical Name : 
        Cellulose, carboxymethyl ether, sodium salt, crosslinked 
4. Empirical Formula : 
        Croscarmellose sodium is a crosslinked polymer of carboxymethylcellulose 
sodium. 
5. Structural Formula : 
                  
6. Molecular weight : 
           90 000–700 000. 
7. Functional category : 
         Tablet and capsule disintegrant. 
8. Applications in pharmaceutical formulation or technology : 
          Croscarmellose sodium is used in oral pharmaceutical formulations as a 
disintegrant for capsules, tablets. In tablet formulation croscarmellose sodium may 
be used in both direct-compression and wet-granulation processes. 
          When used in wet granulations, the croscarmellose sodium should be added 
in both the wet and dry stages of the process (intra- and extragranularly) so that 
the wicking and swelling ability of the disintegrant is best utilized. 
9. Description : 
           Croscarmellose sodium occurs as an odorless, white or grayish white 
powder. 
10. Typical properties : 
    Acidity/alkalinity: pH = 5.0–7.0 in aqueous dispersions. 
    Density (bulk)     : 0.529 g/cm3 for Ac-Di-Sol 
    Density (tapped) : 0.819 g/cm3 for Ac-Di-Sol 
    Density (true)     : 1.543 g/cm3 for Ac-Di-Sol 
    Solubility            : insoluble in water, although croscarmellose sodium rapidly   
                                  swells to 4-8 times its original volume on contact with water. 
                                  Practically insoluble in acetone, ethanol and toluene.        
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CROSPOVIDONE 
40 
:       
1. Nonproprietary Names : 
         BP       : Crospovidone 
         PhEur  : Crospovidonum 
         USPNF: Crospovidone    
2. Synonyms :      
          Crosslinked povidone; E1202; Kollidon CL; Kollidon CL-M; Polyplasdone 
XL; Polyplasdone XL-10; polyvinylpolypyrrolidone; PVPP; 1-vinyl-2-
pyrrolidinone homopolymer. 
3. Chemical Name : 
           1-Ethenyl-2-pyrrolidinone homopolymer 
4. Empirical Formula : 
           The USPNF 23 describes crospovidone as a water-insoluble synthetic 
crosslinked homopolymer of N-vinyl-2-pyrrolidinone. 
5. Structural Formula : 
            
6. Molecular weight : 
             (C6H9NO)n >1 000 000 
7. Functional Category : 
             Tablet disintegrant. 
8. Applications in pharmaceutical formulation or technology : 
             Crospovidone is a tablet disintegrant and dissolution agent used at 2–5% 
concentration in tablets prepared by direct-compression or wet- and dry-
granulation methods. It rapidly exhibits high capillary activity and pronounced 
hydration capacity, with little tendency to form gels. 
             Crospovidone can also be used as a solubility enhancer. With the 
technique of co-evaporation, crospovidone can be used to enhance the solubility 
of poorly soluble drugs. 
9. Description : 
             Crospovidone is a white to creamy-white, finely divided, free flowing, 
practically tasteless, odorless or nearly odorless, hygroscopic powder. 
10. Typical properties : 
             Acidity/alkalinity : pH  5.0–8.0 (1% w/v aqueous slurry) 
             Density                 : 1.22 g/cm3 
             Solubility              : Practically insoluble in water and most common 
                                             organic solvents. 
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XANTHAN GUM 
40
: 
1. Nonproprietary Names : 
          BP: Xanthan gum 
          PhEur: Xanthani gummi 
          USPNF: Xanthan gum 
2. Synonyms : 
          Corn sugar gum; E415; Keltrol; polysaccharide B-1459; Rhodigel; Vanzan NF; 
Xantural 
3. Chemical Name : 
           Xanthan gum. 
4. Functional Category : 
            Stabilizing agent; suspending agent; viscosity-increasing agent. 
5. Applications in pharmaceutical formulation or technology : 
            Xanthan gum is widely used in oral and topical pharmaceutical formulations, 
cosmetics, and foods as a suspending and stabilizing agent.(3–5) It is also used as a 
thickening and emulsifying agent. 
6. Description : 
             Xanthan gum occurs as a cream- or white-colored, odorless, free-flowing, fine 
powder. 
7. Typical properties : 
             Acidity/alkalinity: pH = 6.0–8.0 for a 1% w/v aqueous solution. 
             Melting point      : chars at 270˚C. 
             Solubility            : practically insoluble in ethanol and ether; soluble in cold or 
                                          warm water 
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HYDROXY PROPYL METHYL CELLULOSE 
40
: 
1. Nonproprietary Names : 
       BP: Hypromellose 
       JP: Hydroxypropylmethylcellulose 
       PhEur: Hypromellosum 
       USP: Hypromellose 
2. Synonyms :      
       Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; Methocel; 
methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; 
Metolose; Tylopur. 
3. Chemical Name : 
        Cellulose hydroxypropyl methyl ether 
4. Structural Formula : 
          
5. Functional Category : 
               Coating agent; film-former; rate-controlling polymer for sustained release;      
       stabilizing agent; tablet binder; viscosity  increasing agent.                                 
6. Applications in pharmaceutical formulation or technology : 
         Hypromellose is widely used in oral, ophthalmic and topical 
pharmaceutical formulations. 
Oral use - tablet binder, in film-coating, and as a matrix for use in Extended - 
release tablet formulations. 
Ophthalmic use - added as a thickening agent to vehicles for eye drops and 
artificial tear solutions. 
Topical use - emulsifier, suspending agent, and stabilizing agent in topical gels 
and ointments. 
7.  Description : 
          Hypromellose is an odorless and tasteless, white or creamywhite 
fibrous or granular powder. 
8. Typical Properties : 
         Acidity/alkalinity : pH = 5.5–8.0 for a 1% w/w aqueous solution. 
         Density (tapped)  : 0.557 g/cm3 
         Density (true)       : 1.326 g/cm3 
         Solubility              : soluble in cold water, forming a viscous colloidal 
                                        solution 
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9. Viscosity (dynamic): 
                A wide range of viscosity types are commercially available. Aqueous  
      solutions are most commonly prepared. 
 
               Typical viscosity values for 2% (w/v) aqueous solutions of methocel (Dow     
                                 Chemical Co.) viscosities measured at 20ºC 
  
Methocel grade  
 
Viscosity(cps)  
    K4 M  
 
    4000  
 
    K15M  
 
   15000  
 
    K100M  
 
   100000  
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MICRO CRYSTALLINE CELLULOSE 
40
 : 
1. Nonproprietary Names: 
      BP: Microcrystalline cellulose 
      JP: Microcrystalline cellulose 
      PhEur: Cellulosum microcristallinum 
      USPNF: Microcrystalline cellulose 
2. Synonyms: 
      Avicel PH; Celex; cellulose gel; Celphere; Ceolus KG; crystalline cellulose; 
E460; Emcocel; Ethispheres; Fibrocel; Pharmacel; Tabulose; Vivapur. 
3. Chemical Name : 
       Cellulose 
4. Empirical Formula and molecular weight : 
         (C6H10O5)n       approx. 36,000  
          where n is approx 220.         
5. Structural Formula: 
                
6. Functional Category: 
                 Adsorbent; suspending agent; tablet and capsule diluent; tablet disintegrant. 
7. Applications in pharmaceutical formulation or technology: 
             binder/diluent in oral tablet and capsule formulations where it is used in both 
wet-granulation and direct-compression processes 
8. Description: 
       Microcrystalline cellulose is a purified, partially depolymerized cellulose that 
occurs as a white, odorless, tasteless, crystalline powder composed of porous 
particles. 
9. Typical Properties : 
        Density (bulk)   : 0.337 g/cm3 
        Density (tapped): 0.478 g/cm3 
        Density (true)    : 1.512–1.668 g/cm3 
        Melting range    : chars at 260–270˚C. 
        Solubility           : slightly soluble in 5% w/v sodium hydroxide solution; 
                                    practically insoluble in water, dilute acids, and most organic  
                                   solvents.         
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MAGESIUM STEARATE 
40
 : 
1.Nonproprietary Names: 
      BP/JP/USPF : Magnesium stearate. 
      Ph Eur           : Magnesii stearas. 
2. Synonyms: 
      Magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic acid, 
magnesium salt. 
3. Chemical Name : 
       Octadecanoic acid magnesium salt. 
4. Empirical Formula : 
       C36H70MgO4           
5. Molecular weight : 
       591.34 
6. Structural Formula: 
            [CH3(CH2)16COO]2Mg 
7. Functional Category: 
                USP    : Tablet and capsule lubricant. 
             BP/EP : lubricant, pharmaceutical aid. 
             Others : Glidant, anti-adherent. 
8. Applications in pharmaceutical formulation or technology: 
             Tablet and capsule lubricant, glidant or anti-adherent. 
9. Description: 
       Magnesium stearate is a very fine, light white, precipitated or milled, 
impalpable powder of low bulk density, having a faint odor of stearic acid and a 
characteristic taste. 
10. Typical Properties : 
        Density (bulk)   : 0.159 g/cm3 
        Density (tapped): 0.286 g/cm3 
        Density (true)    : 1.092 g/cm3 
        Melting range    : 117–1508C (commercial samples); 
                                   126–1308C (high purity magnesium stearate). 
        Solubility          : Practically insoluble in ethanol, ether and water; slightly     
                                   soluble in warm benzene and ethanol (95%).            
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TALC 
40
 : 
1. Nonproprietary Names 
           BP      : Purified talc                         
           JP       : Talc 
           PhEur : Talcum 
           USP    : Talc 
2.  Synonyms : 
           Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium 
silicate; Luzenac Pharma; magnesium hydrogen metasilicate; Magsil Osmanthus; 
Magsil Star; powdered talc; purified French chalk; Purtalc; soapstone; steatite; 
Superiore. 
3. Chemical Name : 
           Talc 
4. Empirical Formula : 
           Talc is a purified, hydrated, magnesium silicate, approximating to the formula 
Mg6(Si2O5)4(OH)4. 
5. Molecular Weight : 
           379.3 g/mol   
6. Functional Category : 
            Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule 
lubricant 
7. Applications in pharmaceutical formulation or technology : 
            Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluent. In topical preparations, talc is used as a dusting powder, although it should 
not be used to dust surgical gloves. Talc is additionally used to clarify liquids and is 
also used in cosmetics and food products, mainly for its lubricant properties. 
8. Description : 
             Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, 
crystalline powder. It adheres readily to the skin and is soft to the touch and free from 
grittiness. 
9. Typical properties : 
             Acidity/alkalinity: pH  7–10 for a 20% w/v aqueous dispersion. 
             Solubility            : Practically insoluble in dilute acids and alkalis, 
                                           organic solvents, and water. 
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7. MATERIALS AND METHODS 
                   Table No.1   List of materials and their applications in formulation 
 
Name of the materials 
 
Use in formulation 
 
Metformin HCl 
 
Active ingredient 
 
Gliclazide 
 
Active ingredient 
 
HPMC K100M 
 
Hydrophilic polymer 
 
Xanthan gum 
 
Hydrophilic polymer 
 
MCCP Ph 102 
 
Directly compressible diluent 
 
Iso propyl alcohol 
 
Binder 
 
Cross carmellose sodium 
 
Super disintegrant 
 
Cross povidone 
 
Super disintegrant 
 
Sodium starch glycolate 
 
Super disintegrant 
 
Magnesium stearate 
 
Glidant 
 
Talc 
 
Lubricant 
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                          Table No:2   Equipments used for the Research Work 
 
S.No Insrtuments Used Manufacturing company 
1. 
Digital Balance Shimatzu LB 300 
2. 
Tablet hardness tester Pfizer hardness tester 
3. 
Friability tester Riche Pharma 
4. 
Vernier Caliper Mitutoyo digimatic caliper 
5. 
Dissolution apparatus USP 
Electrolab tablet dissolution 
apparatus 
6. 
Double beam UV Spectrophotometer Shimatzu UV-1800 
7. 
Rotary tablet punching machine Cadmach 
8. 
pH meter Elico Ll120 
9. 
FT-IR Spectrophotometer KBR press model M15 
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7.1. PREFORMULATION STUDIES: 
            Preformulation studies are the first step in the rational development of dosage form. It 
is an investigation of physical and chemical properties of a drug substance alone and when 
combined with excipients. Preformulation investigations are designed to identify those 
physicochemical properties of excipients that may influence the formulation design, method 
of manufacture and pharmacokinetic-biopharmaceutical properties of the resulting product. 
Following are the test performed for the preformulation study. 
7.1.1. Melting point determination of Active ingredients: 
          Definite quantities of active ingredients were taken in different capillary tubes and their 
melting points were determined and matched with standards. 
7.1.2. Determination of λ max: 
Metformin HCl: 
Solution of metformin hydrochloride in water having a known concentration of about 10 
µg/ml was prepared. Solution was then scanned in UV range of 200-400 nm using distilled 
water as a blank and wavelength of maximum absorption was found. 
Gliclazide: 
             An accurately weighed 5 mg of Gliclazide was dissolved in 10 ml of methanol in a 
50 ml volumetric flask and the volume was adjusted up to the mark with distilled water to 
obtain a stock solution of 100 μg/ml. The solution was filtered through Whatman filter paper 
No. 41. 0.2 ml of stock solution was transferred to 10 ml of volumetric flask and volume in 
flask was adjusted to 10 ml with distilled water to obtain a concentration of range of 2μg/ml. 
Solution was scanned in UV range of 200-400 nm using methanol: distilled water (1:4) as a 
blank and wavelength of maximum absorption was found. 
7.1.3. Drug and Drug-Excipient physical compatibility studies: 
           The active ingredients and other excipients were mixed and taken in 2 ml glass vials 
and sealed. Then these glass vials were kept at room temperature and 40
0
C/75%RH for about 
1 month. The samples were withdrawn and analysed for colour change for every 10 days. 
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7.1.4. Chemical compatibility studies by FTIR: 
             IR spectra of drug and polymers and all super disintegrants alone and along with drug  
in KBr pellets at moderate scanning speed between 4000-400cm
-1
 was carried out using 
FTIR. The peak values and the possibility of functional groups shown in spectra were 
compared with standard values. 
7.1.5. CALIBRATION CURVE: 
For Metformin HCl: 
           An ultraviolet (UV) spectrophotometric method in water was used for estimation of 
Metformin HCl in water at 232nm. Absorbance was measured in the concentration range of 
0-10 gm/ml. 
For Gliclazide: 
         An accurately weighed 5 mg of Gliclazide was dissolved in 10 ml of methanol in a 50 
ml volumetric flask and the volume was adjusted up to the mark with distilled water to obtain 
a stock solution of 100 μg/ml. The solution was filtered through Whatman filter paper No. 41. 
An appropriate aliquot portions of 0.2 to 1.0 ml of stock solution were transferred to a series 
of 10 ml volumetric flasks and volume in each flask were adjusted to 10 ml with distilled 
water to obtain a concentration of range of 2-10 μg/ml. 
7.2. FORMULATION DEVELOPMENT: 
Formulation of granules: 
7.2.1. Formulation of sustained release matrix Metformin HCl granules: 
            Different batches of Metformin HCl sustained release layer (F1 to F6) were prepared 
with varying concentrations of different formulation ingredients according to Table no.2. 
Pass all the material in 80 mesh except MCCP Ph102 and it was in 60 mesh. Mix well 
Metformin HCl, polymer, MCCP pH 102 then add Iso propyl alcohol to the mixer, blend well 
to form a coherent mass and dried in an oven and pass the granules in 18 mesh. The granules 
were lubricated with Magnesium stearate and Talc. The amount required for the formulation 
given in the below Table no.2 
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                                          Table No.3     Formulation of SR tablets (Wt in mg) 
Ingredients F1 F2 F3 F4 F5 F6 
Metformin HCl 500 500 500 500 500 500 
  HPMCK100M - - - 100 150 200 
Xanthan gum 100 150 200 - - - 
MCCP Ph102 140 90 40 140 90 40 
Iso propyl alcohol q.s q.s q.s q.s q.s q.s 
Talc 5 5 5 5 5 5 
Mg stearate 5 5 5 5 5 5 
Total wt 750 750 750 750 750 750 
                         
          Table No.4       Polymer concentration used with respect to drug Metformin HCl 
Polymers F1 F2 F3 F4 F5 F6 
HPMCK100M - - - 20 30 40 
Xanthan gum 20 30 40 - - - 
 
7.2.2. Formulation of immediate release Gliclazide layer: 
          An immediate release Gliclazide layer was prepared by direct compression according 
to Table no.4. Pass Gliclazide, talc, Mg stearate in 100 mesh and MCCP pH 102, 
Crospovidone, Cross carmellose sodium, SSG in 60 mesh. Mix the ingredient well. The 
amount required for formulation given in Table no.4. 
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                                     Table No.5   Formulation of IR tablets (Wt in mg) 
Ingredients IR1 IR2 IR3 
Gliclazide 40 40 40 
MCCP pH102 12 12 12 
Croscarmellose sodium 7 - - 
SSG - 7 - 
Crospovidone - - 7 
Indigo blue q.s q.s q.s 
Mg stearate 0.5 0.5 0.5 
Talc 0.5 0.5 0.5 
Total Weight of 1 tablet 60 60 60 
 
Formulation of tablets: 
a) Formulation of sustained release tablets : 
The sustained release tablet was compressed in 13mm diameter with flat biconvex 
tablet. 
b) Formulation of immediate release tablets : 
The immediate release tablet was compressed in 5.5mm diameter with flat biconvex 
tablet. 
7.3. PRE COMPRESSION STUDIES ON GRANULES: 
7.3.1. Bulk Density (Db): 
            It is the ratio of total mass of powder to the bulk volume of powder. It was measured 
by pouring the weight powder (passed through standard sieve # 20) into a measuring cylinder 
and initial weight was noted. This initial volume is called the bulk volume. From this the bulk 
density is calculated according to the formula mentioned below. It is expressed in g/ml and is 
given by 
                                          Db = M/ Vb 
                          Where, M is the mass of powder 
                                       Vb is the bulk volume of the powder. 
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7.3.2. Tapped Density (Dt): 
            It is the ratio of total mass of the powder to the tapped volume of the powder. Volume 
was measured by tapping the powder for 750 times and the tapped volume was noted if the 
difference between these two volumes is less than 2%. If it is more than 2%, tapping is 
continued for 1250 times and tapped volume was noted. Tapping was continued until the 
difference between successive volumes is less than 2 % (in a bulk density apparatus). It is 
expressed in g/ml and is given by 
                                        Dt = M / Vt 
                      Where, M is the mass of powder 
                                   Vt is the tapped volume of the powder. 
 
7.3.3. Angle of Repose (): 
        The friction forces in a loose powder can be measured by the angle of repose (θ). It is an 
indicative of the flow properties of the powder. 
         It is defined as maximum angle possible between the surface of the pile of powder and 
the horizontal plane 
                                    tan () = h / r 
                                     = tan
-1
 (h / r) 
                         Where, is the angle of repose. 
                                      h is the height in cms 
                                      r is the radius in cms. 
       The powder mixture was allowed to flow through the funnel fixed to a stand at definite 
height (h). The angle of repose was then calculated by measuring the height and radius of the 
heap of powder formed. Care was taken to see that the powder particles slip and roll over 
each other through the sides of the funnel. Relationship between angle of repose and powder 
flow property is shown in Table no.5. 
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              Table No.6   : Angle of Repose as an Indication of Powder Flow Properties 
 
S.No. angle of repose Type of flow 
1 ˂20 Excellent 
2 20-30 Good 
3 30-34 Passable 
4 ˃34 Very poor 
 
7.3.4. Carr’s index (or) % compressibility: 
            It indicates powder flow properties. It is expressed in percentage and is given as 
                                               Dt – Db 
                                     I =    ------------ ×100 
                                                     Dt 
                                 Where, Dt is the tapped density of the powder and 
                                 Db is the bulk density of the powder. 
 
  Table No.7: Relationship between % compressibility and flow ability 
% compressibility Flow ability 
5-12 Excellent 
12-16 Good 
18-21 Fair passable 
23-35 Poor 
33-38 Very poor 
>40 Very very poor 
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7.3.5. Hausner ratio: 
            Hausner ratio is an indirect index of ease of powder flow. It is calculated by the 
following formula. 
                                                                             Dt 
                                                Hausner ratio = ------- 
                                                                             Db 
                                                Where, Dt is the tapped density   
                                                            Db is the bulk density. 
Lower hausner ratio (<1.25) indicates better flow properties than higher ones (>1.25). 
 
7.4. POST COMPRESSION STUDIES OF TABLETS: 
7.4.1. Description: 
            The general appearance of a tablet like size, shape, colour, coated or uncoated should 
be observed. It is needed for consumer acceptance and during storage physical changes may 
happen which can be easily matched with description. 
7.4.2. Weight variation: 
           20 tablets were selected randomly from the lot and weighted individually to check for 
weight variation. Weight variation specification as per I.P. is shown in table no.7. 
 
                             Table No.8: Weight Variation Specification as per IP 
Average weight of tablet % deviation  
80 mg or less ±10 
More than 80 mg but less than 250mg ±7.5 
250 mg or more ±5 
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7.4.3. Thickness: 
          It can be dimensionally described and controlled. Thickness may affect the hardness, 
disintegration time and dissolution rate. Tablet thickness can be measured by vernier callipers 
for six tablets. 
7.4.4. Hardness: 
        Hardness or tablet crushing strength (fc ), the force required to break a tablet in a 
diametric compression was measured using Monsanto tablet hardness tester. It is expressed in 
kg/cm2. 
7.4.5. Friability (F): 
         Friability of the tablet determined using Roche friabilator. This device subjects the 
tablet to the combined effect of abrasion and shock in a plastic chamber revolving at 25 rpm 
and dropping a tablet at a height of 6 inches in each revolution. Pre weighed sample of 6 
tablets were placed in the friabilator and were subjected to the 100 revolutions for 4 min. 
Tablets were dusted using a soft muslin cloth and reweighed. The friability (F) is given by the 
formula. 
                                                     Winitial - Wfinal 
                                             F = --------------------- × 100 
                                                         Winitial 
7.4.6. Tablet disintegration time: 
            Tablet disintegration study was performed only for immediate release tablet and for 
the immediate release layer of inlay tablet. Disintegration time was determined using USP 
tablet disintegration tester in distilled water. 
7.4.7. Assay: 
For sustained release tablets: 
Standard preparation: Prepare a solution of metformin hydrochloride in water having a 
known concentration of about 10 µg/ml. 
           Weigh and finely powder 20 tablets. Transfer an accurately weighed portion of the 
powder, equivalent to about 100 mg of metformin hydrochloride, to 100ml volumetric flask. 
Add 70ml of water shake by mechanical means for 15 minutes, dilute with water to volume, 
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and filter, discarding the first 20ml of the filtrate. Dilute 10ml of the filtrate with water to 
100ml, and dilute 10ml of the resulting solution with water to 100ml. 
For immediate release tablets: 
        Crush one tab on butter paper and transfer an accurately an accurately weighed 
Gliclazide, without loss to 500ml volumetric flask, add 20ml methanol sonicate for 5min add 
200ml of diluent and shake mechanically for 60min make vol up to mark with diluent. Filter 
solution to 20ml volumetric flask and dilute up to mark with diluent. Take the absorbance at 
226 nm using diluent as a blank for a background correction. Take absorbance in triplicate of 
a standard solution and duplicate of a sample preparation. 
7.4.8. In vitro dissolution studies: 
            Dissolution study of sustained release and immediate release of different tablet 
formulations were carried out separately. 
Dissolution of sustained release tablet: 
           Apparatus:   USP Type II (Paddle type) 
           Medium    :   6.8 pH phosphate buffer 
           Rpm          :   100 
           Volume     :   900ml 
           Temp        :    37.5°C 
         The study was carried out for 12 hours. 10ml of samples were withdrawn on time 
interval of 1, 3, 6, 9, 12
th 
hour and replaced with fresh medium. Samples were filtered, diluted 
and absorbance was measured at 232 nm using UV- VIS Spectrophotometer. 
Standard preparation: Prepare a solution of metformin hydrochloride in water having a 
known concentration of about 10 µg/ml. 
The percentage of metformin HCl release was calculated. The limit for extended release 
tablet for 12 hours as follows.   
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                                       Table No.9:   Limits for SR formulation release 
Time in hours 500mg tablet, amount dissolved 
1 Between 20% and 40% 
3 Between 45% and 65% 
10 Not less than 85% 
 
Dissolution of immediate release tablet: 
          Dissolution studies were carried out by USP paddle method Type II apparatus at 37± 
0.50° C, taking 900ml of phosphate buffer pH 6.8 as a dissolution medium. Speed of rotation 
of paddle was set at 50rpm. Absorbance of sample was measured at 226 nm by using UV 
spectrophotometer. 
7.4.9. For inlay tablet: 
7.4.9.1. Swelling and erosion studies: 
            The rate of test medium uptake by the pectin polymer was determined by equilibrium 
weight gain method. The inlay tablets were accurately weighed (W0), placed in the basket of 
dissolution apparatus, rotating at 100rpm, 37±0.5°C temperature, using pH 6.8 phosphate 
buffer. After 1, 2, 3, 5, 7, 9 and 12 hours, each basket was removed from the dissolution 
apparatus, the tablet with the pre-weighed mesh was withdrawn from the medium and lightly 
bottled with tissue paper to remove excess test liquid and then reweighed (W1). After the 
swelling studies, the wet samples were then dried in an oven at 80°C for 12 hour time period, 
allowed cooling in desiccators and finally weighed until constant weight was achieved (final 
dry weight, W2). The experiment was performed for 6 times for each time point and fresh 
samples were used for each individual time point. The percentage increase in weight due to 
absorbed liquid or water uptake was estimated at each time point from the following equation 
Swelling % = W1-W0/W0×100, 
Erosion % = W0-W2/W0×100 
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7.4.9.2. Assay of inlay tablet: 
          Assay of inlay tablet containing metformin HCl and gliclazide done by two steps. The 
assay of inlay tablet SR layer containing metformin HCl was analyzed by UV method as 
directed in the assay as of SR tablet. The assay of inlay tablet IR layer containing gliclazide 
was analyzed by UV method as directed in the assay as of IR tablet. 
7.4.9.3. In vitro dissolution profile of inlay tablet: 
          Dissolution medium is separately chosen for both the drugs based on their individual 
solubility and their absorption site in the GIT.  
Separate dissolution conditions were decided, one for each API. 
1. The dissolution of sustained release layer was studied with dissolution medium of 6.8 
pH phosphate buffer for 12 hours as directed in assay of SR tablet. 
2. The dissolution of immediate release layer was studied with dissolution medium of 
6.8 pH phosphate buffer for 30 minutes. 
7.4.9.4. Evaluation of invitro release kinetics: 
To study kinetics, data obtained from in vitro release were plotted in various kinetic models. 
1. Zero order equation: 
If the release rate follows zero order then, the slope can be obtained by plotting % 
drug :released Vs time in hours. It is an ideal release profile to achieve 
pharmacological prolonged action. The release rate was independent of 
concentration. 
                      C=K0t 
                  Where K0 – zero order constant in conc/time 
                              t-time in hours 
2.  First order equation:  
The graph was plotted as log % cumulative drug remaining vs time in hours 
                    log C=log C0-Kt/2.303 
                 where C0- initial concentration of drug 
                            K- first order constant and t-time 
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3. Higuchi kinetics: 
       The graph was plotted as % cummulative drug release vs time in hours 
                    Q = Kt
1/2 
                Where K-constant reflecting design variable system 
                            t-time in hours 
       Hence drug release rate is proportional to the reciprocal of square root of 
time. If the plot yields a straight line, and the slope is one, then the particular 
dosage form is considered to follow higuchi kinetics of drug release. 
4. Hixson and crowell erosion equation: 
        To evaluate the drug release with changes in the surface area and the 
diameter of particles, the data were plotted using the Hixson and cowell rate 
equation. The graph was plotted by cube root of % drug remaining Vs time in 
hours. 
                  Q0
1/3
-Qt
1/3
=KHCt 
               Where Qt      - amount of drug released in time t 
                           Q0     - initial amount of drug 
                           KHC  - rate constant for Hixson crowell equation 
5. Korsmeyer – peppas equation: 
          To evaluate mechanism of drug release, it was further plotted in Peppas 
equation as log cumulative % of drug released Vs time 
                 Mt/M∞= Kt
n
 
            Where Mt/M∞ - friction of drug released at time t 
                  t  – release time 
                  K – kinetic constant 
                  N – diffusional exponent indicative of the mechanism drug release  
          The n value could be obtained from slope of the plot of log cumulative % of 
drug released Vs log time. The results were tabulated. 
 
 
 
 
 
                    
                                                                       MATERIALS AND METHODS 
 
Nandha College of Pharmacy, Erode. Page 44 
 
                      Table No.10   Description of diffusion mechanism 
Diffusion exponent (n) Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45<n<0.89 Anomalous (non-Fickian) diffusion 
0.89 Case-II transport 
n >0.89 Super case-II transport 
 
i. Zero Order Reaction - % Cumulative drug release Vs Time in hrs 
ii. First Order Reaction – Log % Cumulative drug remaining Vs Time in hrs 
iii. Higuchi kinetics - % Cumulative drug release Vs square root of time 
iv. Korsmeyer – Peppas equation- log cumulative % of drug released Vs log 
time 
v. Hixon and Crowell erosion equation – cube root of % drug remaining Vs 
time in hrs 
7.4.10. Stability study: 
       Stability study of optimized inlay tablet was carried out at room temperature and at an 
accelerated condition of 40
0
/75 RH for a period of 3 months. Samples were withdrawn at an 
interval of 1 month for evaluation with respect to physical parameters, assay and dissolution 
studies. 
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8. RESULTS AND DISCUSSION 
8.1. PREFORMULATION STUDIES: 
       The overall objective of preformulation studies is to generate useful information to the 
formulator in developing stable and bioavailable dosage forms that can be mass produced. 
8.1.1. Melting point determination of Active ingredients: 
        Melting point of active ingredients was determined by capillary method. The result was 
shown in table below. 
Drug Specification Observation 
Metformin hydrochloride 222-226
0
C 224.74±0.048
0
C 
Gliclazide 181
0
C 180±0.83
0
C 
 
8.1.2. Determination of λ max: 
For Metformin HCl : 
           Metformin HCl drug solution in water was scanned using UV-Spectrophotometer 
between the range 210-400nm using water as blank and the maximum absorbance (λ max) 
was found at 232nm. 
                                                       Fig No.4.  Spectrum of Metformin HCl 
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For Gliclazide : 
         Gliclazide drug solution was scanned using UV-Spectrophotometer between the range 
210-400nm using methanol:distilled water as blank and the maximum absorbance (λ max) 
was found at 229.5nm. 
                                                 Fig No.5  Spectrum of Gliclazide 
 
8.1.3. Drug-excipient physical compatibility studies: 
       The successful formulation of a stable and effective solid dosage form depends on the 
careful selection of the excipients that are added in the formulation. The drug and excipients 
must be compatible with one another to produce a product that is stable, efficacious and easy 
and safe to administer. 
       The physical compatibility evaluation was performed in visual basis. The study implies 
that the drug, polymer and other excipients were physically compatible with each other as 
there were no changes of physically. The results have been shown in the table no.11.  
8.1.4. Chemical compatibility studies by FTIR: 
       The IR spectral analysis of Metformin hydrochloride, Gliclazide, polymers and other 
excipients was shown from fig no.6 to fig no.18. All the characteristic peaks appear for the 
pure Metformin HCl, Gliclazide and its physical mixture indicating no interaction between 
the two drugs. Both drugs with polymers also show characteristic peaks so, no interaction 
between the drugs and excipients. 
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                       Table No.11: Drug – Excipients Physical compatibility studies. 
S.No Drug+Excipients Description at initial day RT,40
0
C/75%RH 
In days 
10
th 
20
th 
30
th 
1. MH White, Crystalline powder NC NC NC 
2. GL White, Crystalline powder NC NC NC 
3. MH+GL White, Crystalline powder NC NC NC 
4. XG Creamy yellow crystalline powder NC NC NC 
5. HPMC K100M White, creamy crystalline powder NC NC NC 
6. SSG White, free-flowing hygroscopic powder NC NC NC 
7. CP White, crystalline powder NC NC NC 
8. CCS White or greyish white powder NC NC NC 
9. MCC pH102 White, crystalline powder NC NC NC 
10. Mg.S White, crystalline powder NC NC NC 
11. Talc White or greyish white powder NC NC NC 
12. MH+GL+XG White, crystalline powder NC NC NC 
13. MH+GL+HPMC White, crystalline powder NC NC NC 
14. MH+GL+SSG White, crystalline powder NC NC NC 
15. MH+GL+CP White, crystalline powder NC NC NC 
16. MH+GL+CCS White, crystalline powder NC NC NC 
17. MH+GL+All White, crystalline powder NC NC NC 
 
       MH-Metformin HCl, GL-Gliclazide, XG-Xantan gum, HPMC K100M-Hydroxy propyl 
methyl cellulose Grade, SSG-Sodium starch glycolate, CP-Cross povidone, CCS-
Croscarmellose sodium, MCC pH102-Microcrystalline cellulose grade, NC-No Change  
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Chemical compatibility studies by FT-IR: 
Fig No.6  Metformin HCl 
 
 
Fig No.7  Gliclazide 
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Fig No.8 Metformin HCl + Gliclazide 
 
Fig No.9  HPMC 
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Fig No.10  Xanthan gum 
 
Fig No.11  Sodium starch glycolate 
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Fig No.12  Croscarmellose sodium 
 
Fig No.13  Crospovidone 
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Fig No.14  Metformin HCl + HPMC 
 
Fig No.15  Metformin HCl + Xanthan gum 
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Fig No.16  Gliclazide + Sodium starch glycolate 
 
Fig No.17  Gliclazide + Croscarmellose sodium 
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Fig No.18  Gliclazide + Crospovidone 
 
8.1.5. CALIBRATION CURVE: 
a) Metformin hydrochloride: 
      The absorbance of solution of metformin hydrochloride in distilled water was 
observed at 232nm. It was found that the solutions show linearity (R
2
 value 0.9998) in 
absorbance at a concentration of 0-10 µg/ml and obey beer lamberts law. The values 
shown in table no.12 and fig no.19. 
b) Gliclazide:  
              An accurately weighed 5 mg of gliclazide was dissolved in 10 ml of 
methanol in a 50 ml volumetric flask and the volume was adjusted up to the mark 
with distilled water to obtain a stock solution of 100 μg/ml. The solution was filtered 
through Whatman filter paper No. 41. An appropriate aliquot portions of 0.2 to 1.0 ml 
of stock solution were transferred to a series of 10 ml volumetric flasks and volume in 
each flask were adjusted to 10 ml with distilled water to obtain a concentration of 
range of 2-10 μg/ml. 
                                                                     RESULTS AND DISCUSSION 
 
Nandha College of Pharmacy, Erode Page 54 
 
                                 Table No.12:     Calibration curve of Active ingredients 
Metformin hydrochloride Gliclazide 
Concentration 
(µg/ml) 
Absorbance Concentration 
(µg/ml) 
Absorbance 
0 0 0 0 
2 0.281 2 0.159 
4 0.573 4 0.316 
6 0.838 6 0.443 
8 1.119 8 0.611 
10 1.387 10 0.775 
            
                                     Fig No.19   Calibration curve of Metformin HCl 
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                                       Fig No.20   Calibration curve of Gliclazide 
                    
8.2. PRECOMPRESSION STUDY SR FORMULATION: 
8.2.1. Bulk density:  
           The bulk density of various granules prepared with different polymer was measured by 
graduated cylinder. The bulk density was found in the range from 0.499 to 0.522 g/cm
3
. The 
results are presented in Table No.13.   
8.2.2. Tapped density: 
        The tapped density of various granules prepared with different polymer was measured 
by measuring cylinder. The tapped density was found in the range from 0.583 to 0.606 g/cm
3
. 
The results are given in Table No.13. 
8.2.3. Compressibility index: 
        A flow property plays an important role in pharmaceuticals especially in tablet 
formulation because improper flow may cause more weight variation. Values of Carr’s Index 
(Compressibility) below 15% usually give rise to good flow properties but readings above 
25% indicate poor flow properties. The compressibility index of various granules prepared 
with different polymer using bulk density and tapped density data was calculated. It was 
y = 0.0765x + 0.0013 
R² = 0.9988 
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found in the range 13.5 to 14.5% and hence they exhibit good flow property. The results are 
given in Table No.13.  
8.2.4. Hausner’s ratio: 
         Hausner ratio is an indirect index of ease of powder flow. Lower hausner ratio (<1.25) 
indicates better flow properties than higher ones (>1.25). The hausner ratio of various 
granules prepared with different polymer was calculated by using bulk density and tapped 
density data. It was found in the range of 1.14 to 1.17 which indicates better flow property. 
The results are given in Table No.13. 
8.2.5. Angle of repose (θ): 
          The angle of repose of various granules prepared with different polymer was measured 
by funnel method. Angle of repose was found in the ranges from 24.80
0
 to 26.60
0
. So, also 
evidenced with angle of repose that granules have a good flow property. The results are given 
in Table No.13. 
                                    Table No.13:   Pre compression study SR formulation 
Formulation Bulk 
density
*
 
g/cm
3 
Tapped 
density* 
g/cm
3 
Compressibility 
index
*
 g/cm
3 
Hausner’s 
ratio
*
 
Angle of 
repose
* 
F1 0.516±0.002 0.597±0.013 13.5±0.001 1.15±0.001 25.39±0.681 
F2 0.522±0.004 0.606±0.034 14.0±0.029 1.15±0.009 26.20±0.292 
F3 0.507±0.031 0.590±0.019 14.5±0.053 1.17±0.040 25.88±0.433 
F4 0.499±0.020 0.583±0.051 14.4±0.003 1.16±0.051 24.80±0.111 
F5 0.500±0.014 0.592±0.022 14.3±0.039 1.14±0.028 25.64±0.395 
F6 0.517±0.008 0.576±0.011 14.1±0.011 1.16±0.021 26.60±0.105 
          
*
 Mean ± SD (n=3) 
8.3. POST COMPRESSION STUDIES OF SR TABLETS: 
8.3.1. Weight variation: 
          The theoretical average weight of the various formulated tablets are 750mg and weight 
variation of various formulation are depicted in Table No.14. The percentage deviation of the 
weight was within 5% as per monograph. 
                                                                     RESULTS AND DISCUSSION 
 
Nandha College of Pharmacy, Erode Page 57 
 
8.3.2. Hardness: 
         The hardness of various tablet formulation was shown in Table No.14. The hardness of 
the tablet was found in the ranges from 6.4 to 6.6 Kg/cm
2
. So, it was the sufficient hardness 
for tablet coating, transporting and packing. 
                          Table No.14: Post compression parameters of SR formulations 
Formulation Weight 
variation
*  
Hardness* 
(Kg/cm
2
) 
Thickness* 
(mm) 
Friability* 
(%) 
Drug 
content*(%) 
F1 750±4.15 6.5±0.255 6.48±0.113 0.38±0.102 98.30±0.05 
F2 750.4±6.1 6.4±0.491 6.42±0.017 0.49±0.026 98.03±0.06 
F3 749.7±5.83 6.6±0.204 6.61±0.129 0.58±0.034 98.13±0.01 
F4 749.6±7.97 6.4±0.258 6.63±0.092 0.69±0.045 98.33±0.04 
F5 751.1±4.21 6.5±0.273 6.62±0.089 0.30±0.019 99.56±0.03 
F6 749.2±5.82 6.6±0.418 6.52±0.214 0.69±0.040 99.80±0.02 
  *Mean ± SD (n=3) 
8.3.3. Thickness: 
        The thickness of the various tablet formulation was shown in Table No.14. The 
thickness of the tablet was found in the ranges from 6.42 to 6.63 mm. It was important for 
packing of tablet and acceptance. 
8.3.4. Friability: 
       The friability of the various tablet formulation was shown in table no.14. The friability of 
the tablet was found in the ranges from 0.30 to 0.69%. The values are within limit of the 
official monograph i.e., not more than 1%. 
8.3.5. Drug content: 
      The content of the various formulations was analyzed by UV spectrometric method. It 
was very important for the release percentage from the amount present in the tablet. The 
percentage of drug found in the tablet ranges from 98.03 to 99.80% and was within the limits. 
The drug content of various formulations was shown in table no.14.   
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8.3.6. In Vitro Dissolution study of SR tablet: 
                     Table No.15: In vitro dissolution profile SR tablet* 
Formulation Time in hrs 
1 3 6 9 12 
F1 69.83±0.399 83.59±0.805 95.32±0.887 97.97±0.510 99.25±0.715 
F2 63.45±0.947 79.98±0.572 93.27±0.718 96.32±0.542 98.16±0.622 
F3 57.64±0.781 74.77±0.526 84.57±0.341 94.13±0.778 98.59±0.722 
F4 64.52±0.862 75.81±0.940 89.98±0.557 96.75±0.989 99.93±0.680 
F5 52.19±0.685 72.93±0.557 84.75±0.663 93.26±0.560 99.14±0.887 
F6 30.72±0.546 51.96±0.385 72.43±0.778 89.17±0.904 98.58±0.933 
          
              In vitro dissolution profile of various formulations studied. From the results of in 
vitro dissolution studies of sustained release formulations it was observed that the 
formulation  F1 to F6, formulation F6 having a release profile up to 12 hours was selected for 
formulation of inlay tablet. It was concluded that the drug release from the hydrophilic 
polymer HPMC K100M shows the better release rate in which the concentration of polymers 
respect to the drug was 40% w/w. So, as the polymer concentration increases the release time 
also increases. All the polymers showed the sustained release property. Among both the 
polymers HPMC K100M shows the release up to 12 hours at higher concentration with other 
polymer xanthan gum. Among xanthan gum and HPMC K100M, latter was better polymer 
due to its gel swelling and diffusion mechanism. Different concentrations of polymers were 
used in the formulation F4, F5, F6. Sustained release was found best with higher 
concentration of polymer because as the concentration increases, swelling increases and thus 
drug release rate decreases causing sustained release.  
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                           Fig No.21.  Comparitive dissolution profile of F1, F2,F3 
 
                     
                          Fig No.22  Comparitive dissolution profile of F4, F5, F6 
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                 Fig No.23  In Vitro dissolution profile of various SR formulations 
                 
               
8.4. PRE COMPRESSION STUDY FOR IR FORMULATION: 
8.4.1. Bulk density:  
          The bulk density of various powder mixed blends prepared with different 
superdisintegrants was measured by graduated cylinder. The bulk density was found in the 
range from 0.52 to 0.55 g/cm
3
. The results are presented in Table No.16. 
8.4.2. Tapped density: 
         The tapped density of various powder mixed blends prepared with different 
superdisintegrants was measured by measuring cylinder. The tapped density was found in the 
range from 0.60 to 0.63 g/cm
3
. The results are presented in Table No.16. 
8.4.3. Compressibility index: 
          A flow property plays an important role in pharmaceuticals especially in tablet 
formulation because improper flow may cause more weight variation. Values of Carr’s Index 
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(Compressibility) below 15% usually give rise to good flow properties but readings above 
25% indicate poor flow properties.  The compressibility index of various powder mixed 
blends prepared with different super disintegrants was calculated using bulk density and 
tapped density data. It was found in the range 13.50 to 14.20% and hence they exhibit good 
flow property. The results are given in Table No.16. 
8.4.4. Hausner’s ratio: 
         Hausner ratio is an indirect index of ease of powder flow. Lower hausner ratio (<1.25) 
indicates better flow properties than higher ones (>1.25). The hausner ratio of various powder 
mixed blends prepared with different superdisintegrants, was calculated by using bulk density 
and tapped density data. It was found in the range of 1.14 to 1.15 which indicates better flow 
property. The results are given in Table No.16. 
8.4.5. Angle of repose (θ): 
          The angle of repose of various powder mixed blends prepared with different 
superdisintegrants was measured by funnel method. Angle of repose was found in the ranges 
from 22.9
0
 to 23.5
0
. So, also evidenced with angle of repose that granules have a good flow 
property. The results are given in Table No.16. 
                    Table No.16: Pre compression study for IR formulation 
Formulation Bulk 
density
*
 
g/cm
3 
Tapped 
density* 
g/cm
3 
Compressibility 
index
*
 g/cm
3 
Hausner’s 
ratio
*
 
Angle of 
repose
* 
F1 0.52±0.013 0.61±0.001 14.20±0.625 1.15±0.018 22.9±0.259 
F2 0.55±0.002 0.60±0.006 13.74±0.829 1.15±0.014 23.5±0.621 
F3 0.53±0.007 0.63±0.003 13.50±0.120 1.14±0.012 23.5±0.860 
            * Mean ± SD (n=3) 
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8.5. POST COMPRESSION OF IR TABLET: 
8.5.1. Weight variation: 
          The theoretical average weight of various formulated tablets was 60mg and weight 
variation of various formulation are depicted in Table No.17. The percentage deviation of the 
weight was within 10% as per monograph. 
8.5.2. Hardness: 
         The hardness of various tablet formulation was shown in Table No.17. The hardness of 
tablet was found in the ranges from 3.06 to 3.5 Kg/cm
2
. So, it was the sufficient hardness for 
tablet coating, transporting and packing. 
8.5.3. Thickness: 
        The thickness of the various tablet formulation was shown in Table No.17. The 
thickness of the tablet was found in the ranges from 2.91 to 2.94 mm. It was important for 
packing of tablet and acceptance. 
8.5.4. Friability: 
       The friability of the various tablet formulation was shown in Table No.17. The friability 
of the tablet was found in the ranges from 0.61 to 0.67%. The values are within limit of the 
official monograph i.e., not more than 1%. 
8.5.5. Disintegration time: 
      The disintegration time of various tablet formulation was shown in Table No.17. The 
disintegration time was found to be least for the formulation IR3.   
8.5.6. Drug content: 
      The content of the various formulations was analyzed by UV spectrometric method. It 
was very important for the release percentage from the amount present in the tablet. The 
percentage of drug found in the tablet ranges from 100.27 to 100.38% and was within the 
limits. The drug content of various formulations was shown in table no.17. 
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                         Table No.17:    Post compression study of IR Tablet 
Formulation Weight 
variation
* 
Hardness* 
(Kg/cm
2
) 
Thickness
* 
(mm) 
Friability* 
(%) 
Disintegrat
ion time* 
(sec) 
%Drug 
content* 
IR1 100.38±0.7 3.53±0.255 2.91±0.92 0.67±0.329 32±3.719 100.38±0.728 
IR2 100.32±0.6 3.20±0.045 2.98±0.69 0.61±0.441 24±2.281 100.32±0.623 
IR3 100.27±0.7 3.06±0.076 2.94±0.80 0.66±0.019 13±1.005 100.27±0.761 
             * Mean ± SD (n=3) 
8.5.7. In vitro dissolution release profile and optimization of IR tablet: 
      In vitro dissolution release profile of various formulations were studied. On comparision 
of all the formulations, Formulation IR3 released 89% of drug within 15 mins. So 
Formulation IR3 containing crospovidone was found to be best among all the three 
formulations, this might be due to its less swelling and greater water uptake tendency 
compared to other super disintegrants croscarmellose sodium and SSG. 
                     Table No.18: In vitro dissolution profile of IR tablet 
Time in min Formulation 
IR1 
 
IR2 
 
IR3 
 
5 41.12±1.07 42.39 ±1.54 51.55±1.92  
10 59.95±1.52 59.41±1.41 63.70± 1.40 
15 81.93±1.28 83.92±1.79 89.54± 1.71 
20 92.81±1.02 93.23±1.83 99.48± 1.29 
30 96.31±1.53 94.64±1.62        99.79±1.22 
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                       Fig No.24   In Vitro dissolution profile of various IR formulations 
                   
8.6. FORMULATION AND EVALUATION OF INLAY TABLETS: 
       From the results of in vitro dissolution studies of IR and SR formulations 
                           Table No.19 : Formulation for inlay tablets (Wt in mg) 
Sustained release 
layer (F) 
Per tablet (mg) Immediate release 
layer (F) 
Per tablet (mg) 
Metfromin HCl 500 Gliclazide 40 
HPMC K100M 200 MCCP pH 102 12 
MCCP pH102 40 Crospovidone 7 
Iso propyl alcohol q.s Mg stearate 0.5 
Talc 5 Talc 0.5 
Mg stearate 5 Indigo blue q.s 
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                                 Table No.20:   Evaluation of inlay tablets 
Parameters Results 
Uniformity of weight*(mg) 810.62±5.49 
Tablet thickness*(mm) 6.952±0.041 
Hardness*(kg/cm
2
) 6.73±0.416 
Friability*(%) 0.042±0.022 
Disintegration time*(sec) 2.83±0.065 
                *mean ± SD (n=3) 
All the parameters shown in table complies with the official monograph 
8.6.1. Swelling and erosion behaviour of inlay tablets: 
                Table No.21: Swelling and erosion behaviour of inlay tablets 
Time in hours % of swelling % of erosion 
0 0 0 
1 6.75±0.086 2.086±0.261 
2 7.41±0.045 3.124±0.167 
3 9.34±0.027 3.726±0.048 
5 10.92±0.114 4.461±0.087 
7 11.29±0.223 4.519±0.097 
9 13.87±0.074 4.702±0.056 
12 15.63±0.029 4.873±0.049 
 
          The results showed in Table No.21 says that the SR tablets maintained their integrity 
gave increased swelling through the course of study. Thus the extent of swelling increases 
with amount of swellable polymer. 
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8.6.2. Drug content: 
      Drug content of inlay tablet containing metformin HCl and gliclazide was done by two 
steps. The results were shown in Table No.22 which were within the limits. 
                                    Table No.22: Drug content of the inlay tablet 
Inlay tablet % Drug content 
Metformin hydrochloride 99.43±0.52 
Gliclazide 100.29±0.48 
  
8.6.3. In vitro release profile of inlay tablet: 
Data obtained from the dissolution profile of SR and IR layer was shown in table no.23. 
                 Table No.23: In vitro dissolution profile of SR and IR layer* 
Immediate release layer Sustained release layer 
Time in min Cumulative % of 
drug release 
Time in hours Cumulative % of 
drug release 
5 50.52±1.83 1 28.35±0.37 
10 65.30± 1.50 3 48.53±0.61 
15 88.27± 1.46 6 69.28±0.52 
20 99.04± 1.71 9 88.61±0.46 
30        99.64±1.42 12 98.42±0.36 
             *mean ± SD (n=6) 
8.6.4. Kinetic study of inlay tablet: 
        Data obtained from in vitro release of metformin hydrochloride from the inlay tablets 
were fitted in various kinetic models and results are tabulated in the Table No.24. 
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                                Table No.24: Data for various kinetic models 
Time 
(hours) 
% cum. 
Drug 
release 
% cum 
drug 
remaining 
Log % 
cum drug 
remaining 
Square 
root of 
time 
Log 
time 
Log % 
cum. 
Drug 
release 
Cube root 
of % drug 
remaining 
0 0 100 2.000 0 0 0 4.641 
1 28.35 71.65 1.855 1 0 1.452 4.153 
3 48.53 51.47 1.711 1.732 0.477 1.686 3.719 
6 69.28 30.72 1.487 2.449 0.778 1.840 3.131 
9 88.61 12.39 1.214 3 0.954 1.922 2.540 
12 98.42 1.58 0.198 3.464 1.079 1.993 1.164 
 
                                              Fig No.25  Zero order kinetics of SR 
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                                           Fig No.26   First order kinetics of SR 
                
                                 
                                       Fig No.27  Higuchi diffusion kinetics of SR 
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                                     Fig No.28  Hixson Crowell equation of SR 
               
                                     Fig No.29  Korsmeyer Peppas equation of SR 
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                            The drug release data obtained was extrapolated by Zero order, First order, 
Higuchi square root equation, Hixson crowell cube root equation and Korsmeyer peppas 
equation to know drug release mechanism from this formulation. 
                            Regression coefficient (R
2
) showed good linearity with Zero order equation 
(0.9243) when compared to First order equation (0.8852) indicating that drug release is 
independent of concentration of the drug. 
                           In vitro release profile could be best expressed by Higuchi square root 
equation as plots showed highest linearity (0.9997) when compared to Hixson crowell cube 
root equation (0.9711). It confers that drugs are released by diffusion. 
                           To confirm diffusion mechanism, the data was fitted to Korsmeyer peppas 
equation. Formulation showed good linearity with diffusion exponent(n) value 0.4999 
indicating that diffusion was predominant mechanism of drug release fron this formulation 
indicating that drug release mechanism was Non fickian or anomalous release (0.45<n<0.89). 
It can be inferred that release was dependant both on drug diffusion and polymer relaxation, 
which appears to indicate a coupling of diffusion and erosion mechanisms so called 
anomalous diffusion.                                       
8.6.5. Determination of drug release mechanism of immediate release layer from 
optimized inlay tablets: 
                                  Table No.25: Data for various kinetic models 
Time in min % Drug release % To be released Log % drug remaining 
0 0 100 2.000 
5 50.52 49.48 1.694 
10 65.30 34.7 1.540 
15 88.27 11.73 1.069 
20 99.04 0.96 -0.017 
30 99.64 0.36 -0.443 
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                                                Fig No.30  First order kinetics of IR  
               
                                                
                                        Fig No.31    Zero order kinetics of IR 
              
From the above graphs it was concluded that gliclazide was following first order of release 
with regression value of 0.9345. 
8.6.6. Stability study: 
               The optimised inlay tablets were subjected to stability studies and results were 
tabulated in Table No.26 and Table No.29. 
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                         Table No.26:  Stability study at 40˚C/75% RH     
Parameters 1
st
 month 2
nd
 month 3
rd
 month 
RT 40˚C RT 40˚C RT 40˚C 
Uniformity of 
weight**(mg) 
810.72±1.4 810.67±1.2 810.64±1.3 810.66±1.8 810.62±1.5 810.63±1.4 
Thickness*(mm) 6.952±0.09 6.954±0.09 6.957±0.07 0.950±0.09 0.955±0.09 0.951±0.08 
Hardness*(kg/cm
2
) 6.74±0.693 6.74±0.682 6.74±0.684 6.74±0.697 6.74±0.691 6.74±0.688 
D.time*(sec) 2.77±0.261 2.76±0.285 2.77±0.229 2.77±0.249 2.77±0.237 2.77±0.289 
Friability*(%) 0.16±0.232 0.16±0.325 0.17±0.211 0.16±0.281 0.16±0.261 0.16±0.247 
                  
Table No.27 Assay and dissolution profile of inlay tablet at stability study at 40˚C/75% 
RH                                    
Intervals in 
months 
Drug % drug content* % cumulative release* 
RT 40˚C RT 40˚C 
1
st
 month Metformin HCl 100.28±0.79 100.45±0.67 97.97±0.48 97.62±0.82 
Gliclazide 100.16±0.89 100.28±0.78 98.42±0.22 97.32±0.19 
2
nd
 month Metformin HCl 100.24±0.74 100.38±0.59 97.91±0.72 97.51±0.42 
Gliclazide 100.15±0.68 100.22±0.64 97.57±0.59 96.37±0.48 
3
rd
 month Metformin HCl 100.22±0.71 100.36±0.55 97.83±0.28 97.49±0.53 
Gliclazide 100.14±0.66 100.20±0.62 98.72±0.39 96.24±0.95 
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10. SUMMARY AND CONCLUSION 
          The present research endeavour is directed towards the development of inlay tablets 
of Metformin HCl as sustained release and Gliclazide as immediate release. 
           All the formulations were evaluated for physical characteristics, disintegration, In 
Vitro dissolution study and stability study. Following conclusions have been made from the 
present study. 
 The possibility of drug excipients interaction was investigated by FTIR. The physical 
characteristics of all the blended formulations were satisfactory. 
 The prepared tablets of sustained release and immediate release were evaluated for 
assay, weight variation, hardness, thickness, friability and disintegration time and 
results were found to be within official limits. 
 The disintegration studies showed that immediate release formulation IR3 prepared by 
direct compression technique using crospovidone was best disintegrating within 13 
sec. 
 The In Vitro dissolution studies were performed for all the IR formulations. Among 
all the formulations, IR3 containing crospovidine showed fastest release i.e., 95.48% 
of drug within 10mins. 
 In Vitro dissolution study of SR formulations was performed and release profile of 
formulation F6 containing 40% concentration of HPMC K100 M was best when 
compared to other five formulations. 
 Inlay tablet formulation was prepared using optimum formulation of sustained release 
granules and immediate release granules. Initially Metformin HCl granules were filled 
in the die cavity, over that immediate release tablet was placed and then compressed 
finally to get an inlay tablet.  
 The inlay tablets evaluated for assay, weight variation, hardness, thickness, friability 
and disintegration time and the results were found to be within the official limits. 
 The dissolution data of the optimized batch was subjected to study the In Vitro release 
kinetics. The results showed that the IR layer of inlay tablet formulation followed the 
first order release kinetics and the drug release kinetics of SR layer of inlay tablet 
formulation corresponds best to Higuchi’s model and drug release mechanism as per n 
value of Korsmeyer and Peppas model appeared to be a complex mechanism of 
swelling, diffusion and erosion with zero order release kinetics. 
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 The stability study was conducted for 3 months under room temperature and 
45
0
C/75% RH. Finally after the duration, the product was analysed for physical 
appearance, disintegration time, dissolution study and assay. The results obtained 
were found to be within the specification limits. 
                                         Thus from the results of the present study it was concluded 
that anti-diabetic drugs with different mechanism of action formulated as inlay tablet 
improved glycemic control by releasing drug up to 12 hours and there by reducing 
frequency of administration and improving patient compliance. 
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